1. Home
  2. ZURA vs SIFY Comparison

ZURA vs SIFY Comparison

Compare ZURA & SIFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$4.84

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Logo Sify Technologies Limited

SIFY

Sify Technologies Limited

N/A

Current Price

$13.79

Market Cap

1.2B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ZURA
SIFY
Founded
2022
1995
Country
United States
India
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
1.2B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
ZURA
SIFY
Price
$4.84
$13.79
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
1.7M
19.1K
Earning Date
05-14-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$14.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.88
$10.09
52 Week High
$7.25
$17.85

Technical Indicators

Market Signals
Indicator
ZURA
SIFY
Relative Strength Index (RSI) 36.32 37.19
Support Level $4.22 $13.50
Resistance Level $5.94 $15.29
Average True Range (ATR) 0.37 0.62
MACD -0.12 -0.08
Stochastic Oscillator 12.18 28.64

Price Performance

Historical Comparison
ZURA
SIFY

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About SIFY Sify Technologies Limited

Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.

Share on Social Networks: